Soluble receptor for advanced glycation end-products and progression of airway disease

BMC Pulmonary Medicine

Table 2 Correlations between plasma sRAGE concentrations and baseline demographics

	All		Non-smokers		Smokers without COPD		Smokers with COPD
	(n = 295)		(n = 32)		(n = 212)		(n = 51)
	r	p-value	r	p-value	r	p-value	r	p-value
Age	-0.053	0.362	0.106	0.563	-0.110	0.109	-0.061	0.670
BMI	-0.139	0.017*	0.260	0.151	-0.162	0.018*	-0.272	0.053
Pack-year	-0.149	0.010*	-	-	-0.072	0.295	-0.262	0.063
FVC	0.130	0.026*	0.119	0.518	0.140	0.042*	0.131	0.360
FVC % predicted	0.190	0.001**	0.042	0.829	0.189	0.006**	0.163	0.252
FEV1	0.126	0.030*	0.116	0.526	0.133	0.054	0.151	0.291
FEV1 % predicted	0.136	0.020*	0.044	0.821	0.164	0.017*	0.176	0.217
FEV1/FVC	-0.029	0.620	0.070	0.245	-0.064	0.353	0.138	0.335

*: p < 0.05; **: p < 0.01 (correlation with plasma sRAGE levels by Spearman’s rank correlation coefficient).
BMI, Body mass index; COPD, Chronic obstructive pulmonary disease; FEV ₁, Forced expiratory volume in 1 s; FVC, Forced vital capacity.

ISSN: 1471-2466